Survodutide vs Tirzepatide
Boehringer Ingelheim's GLP-1/glucagon dual agonist versus Eli Lilly's GIP/GLP-1 dual agonist for obesity and metabolic disease.
Last updated: January 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Survodutide
Dossier overview
Tirzepatide
Dossier overview
Overview
Survodutide and tirzepatide represent two different approaches to dual-hormone agonism for metabolic disease. While tirzepatide targets GIP and GLP-1 receptors, survodutide targets glucagon and GLP-1 receptors. Both aim to enhance weight loss and metabolic outcomes beyond single-agonist GLP-1 therapies.
This comparison matters because both compounds demonstrate significant weight loss potential, but through distinct mechanisms that may have different implications for efficacy and safety.
Key Facts
| Aspect | Survodutide | Tirzepatide |
|---|---|---|
| Developer | Boehringer Ingelheim | Eli Lilly |
| Targets | GLP-1 + Glucagon | GIP + GLP-1 |
| FDA Status | Phase 3 (not approved) | FDA approved |
| Administration | Subcutaneous injection | Subcutaneous injection |
Mechanism Comparison
| Aspect | Survodutide | Tirzepatide |
|---|---|---|
| GLP-1 Activity | Agonist | Agonist |
| Second Target | Glucagon receptor | GIP receptor |
| Unique Feature | Glucagon increases energy expenditure | GIP amplifies GLP-1 effects |
| Metabolic Action | Thermogenesis + appetite | Insulin secretion + appetite |
Survodutide Mechanism
The glucagon component of survodutide is theorized to:
- Increase hepatic glucose output (counterbalanced by GLP-1)
- Stimulate lipolysis and fat oxidation
- Increase energy expenditure
- Reduce hepatic steatosis
Tirzepatide Mechanism
The GIP component of tirzepatide is theorized to:
- Amplify insulin secretion synergistically with GLP-1
- Enhance adipose tissue function
- Improve lipid metabolism
- Potentially reduce GI side effects
Clinical Trial Data
Survodutide Phase 2 Results
The Phase 2 trial in obesity showed promising results:
| Dose | Weight Loss (48 weeks) |
|---|---|
| 4.8mg | ~18.7% |
| 6.0mg | ~19.5% |
- Significant reductions in liver fat observed
- NAFLD-focused trials showing particular promise
Tirzepatide Phase 3 Results (SURMOUNT)
| Trial | Dose | Weight Loss |
|---|---|---|
| SURMOUNT-1 | 15mg | -22.5% |
| SURMOUNT-2 | 15mg | -15.7% (T2D) |
Efficacy Comparison
| Outcome | Survodutide | Tirzepatide |
|---|---|---|
| Max Weight Loss | ~19.5% (Phase 2) | ~22.5% (Phase 3) |
| Data Maturity | Phase 2 | Phase 3 + approved |
| Liver Fat Reduction | Strong signal | Modest improvement |
| HbA1c Reduction | Significant | -2.3% (15mg) |
Important: Direct comparison is limited as survodutide data is from earlier-phase trials with smaller populations.
NASH/MAFLD Focus
| Aspect | Survodutide | Tirzepatide |
|---|---|---|
| NASH Trials | SYNCHRONY (Phase 2b positive) | SYNERGY-NASH (Phase 2) |
| Liver Focus | Primary development pathway | Secondary indication |
| Fibrosis Data | Promising | Early data positive |
Survodutide may have advantages for fatty liver disease due to glucagon’s effects on hepatic lipid metabolism.
Side Effect Profile
Gastrointestinal Effects
| Side Effect | Survodutide | Tirzepatide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| Diarrhea | Common | Common |
| Constipation | Less common | Common |
Unique Considerations
| Concern | Survodutide | Tirzepatide |
|---|---|---|
| Blood Glucose | Glucagon may transiently raise | Glucose-lowering |
| Heart Rate | Data emerging | Modest increase |
| Pancreatitis Risk | Unknown (monitoring) | Low (monitored) |
Regulatory and Development Status
| Aspect | Survodutide | Tirzepatide |
|---|---|---|
| Phase | Phase 3 | Approved |
| Obesity Approval | Pending | Yes (Zepbound) |
| T2D Approval | Pending | Yes (Mounjaro) |
| NASH Indication | Primary focus | Under investigation |
| First Approval | Expected 2025-2026 | 2022 |
Evidence Quality
| Factor | Survodutide | Tirzepatide |
|---|---|---|
| Trial Phase | Phase 2-3 | Phase 3 complete |
| Sample Sizes | Hundreds | Thousands |
| Duration | Up to 48 weeks | Up to 72 weeks |
| CV Outcomes | Not yet studied | Ongoing |
| Real-World Data | None | Emerging |
Cost and Access
| Factor | Survodutide | Tirzepatide |
|---|---|---|
| Availability | Not available (trials only) | Widely available |
| List Price | Unknown | ~$1,000/month |
| Insurance | N/A | Variable coverage |
Summary
| Factor | Survodutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1/Glucagon | GIP/GLP-1 |
| Evidence Level | High (Phase 2-3) | High (Phase 3 + approved) |
| Weight Loss | ~19% (Phase 2) | ~22% (Phase 3) |
| Unique Strength | Liver fat reduction | Proven efficacy + availability |
| Availability | Investigational | FDA approved |
Key Takeaways
- Different dual mechanisms: Survodutide adds glucagon while tirzepatide adds GIP to the GLP-1 foundation
- Tirzepatide is proven: FDA-approved with extensive Phase 3 data and real-world experience
- Survodutide shows promise: Strong Phase 2 results, especially for liver disease
- Liver disease potential: Survodutide may have advantages for NASH/MAFLD
- Cannot directly compare: Different trial phases and populations limit head-to-head conclusions
This comparison is for educational purposes only. Survodutide is investigational and not approved. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.